BASF's Ambitions Outrun Its Paperwork as October 28 Looms

BASF has spent the past few days stacking up announcements — a chip-materials expansion in Taiwan, a nylon joint venture with Highsun, a public push for Evonik and a fresh endorsement from Bernstein. What the flurry has not produced is a single completed transaction. For investors, that gap between intent and execution is the story, and the third-quarter release on October 28 at 7.00 CET (press conference at 10.30 CET) is the next hard datapoint against which to measure it.

Taiwan: a memorandum, not a plant

The company intends to broaden its Kuanyin site in Taoyuan to serve advanced semiconductor materials, under a letter of intent signed with Taiwan's Ministry of Economic Affairs. The plan bundles three elements: additional production capacity, expanded quality analysis and a larger innovation center, all aimed at supporting technologies below 2 nanometers. Capacity alone does not capture the scope — the analytical and technical support functions are part of the package, and any assessment that looks only at potential volumes misses a substantial piece of the design.

The status of the project matters as much as its content. A memorandum of intent is not a completed build-out, and the Taiwan plans describe a possible extension of the business rather than evidence that extra revenue is already flowing. The real test is operational: whether the announced expansions turn into usable capabilities in production, quality control and innovation. Concrete progress on the build-out would tell investors more than a restatement of the intention.

Highsun talks stay non-binding

A similar distinction applies to the nylon discussions. BASF and Highsun Holding Group signed a non-binding letter of intent on Monday to examine combining their European activities along the polyamide-6 value chain in a possible 50:50 joint venture. The review also covers worldwide extrusion activities outside North America.

No binding agreement exists and no combination has been carried out, so the venture cannot be valued as a completed restructuring. It is a strategic option whose realization remains open — and should be kept separate from the current operating trend when reading the upcoming figures.

Evonik: an offer already rebuffed

On the takeover front, chief executive Markus Kamieth publicly campaigned for an acquisition of Evonik, according to Reuters, holding out extensive job and site guarantees. Evonik has reportedly rejected an initial BASF offer of around €22.15 per Evonik share as too low. Here too the focus is a possible transaction rather than a closed purchase, with Kamieth's public backing and the rejection marking the two sides' differing positions.

Bernstein Research reiterated its "Outperform" rating on BASF on Tuesday with a €61 price target. Analyst James Hooper's sector outlook flagged the potential influence of takeovers and mergers as well as the agricultural cycle, including the possible Evonik deal. The call was a confirmation, not an upgrade, and it ties the stock's valuation to strategic possibilities and cyclical factors without prejudging how the takeover talks end.

Awards are not scale-up

Recognition does not shift these distinctions. On October 16, BASF received the MATERIALICA Award and second place at the Fakuma Innovation Award for two polyamide-6 recycling pilot projects. The company stressed at the same time that industrial deployment would require further development and scaling — technical acclaim and commercial use sit at different stages of maturity.

What the quarter can settle

The risk is straightforward: investors may price in the economic benefit of these initiatives before BASF actually delivers it. Taiwan remains at the declaration stage, and the Highsun venture is explicitly under non-binding review; treating either as a secured earnings support would overstate its status. In an unfavorable scenario the projects linger at their current stages, and the strategic narrative fails to be confirmed by operating contributions — a particular vulnerability for anyone positioning for quick results.

Until the projects advance, a sober approach is to keep potential upside and realized results in separate columns. Evidence of implementation would strengthen the bullish reading; its absence would argue for scrutinizing near-term earnings expectations more critically. The October 28 release is the next scheduled occasion to judge the operating side of the business — and for the Taiwan plans the yardstick stays the same: not the letter of intent, but its execution, would have to carry any richer valuation.